Overweight Clinical Trials in Dallas, Texas

12 studies are recruiting for overweight in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Velocity Clinical Research - Dallas /ID# 282734, Dallas, Texas

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

   The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cedar Health Research, Dallas, Texas

   Locations

   62 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07770841 on ClinicalTrials.gov

3. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Velocity Clinical Research, Dallas, Dallas, Texas

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

4. A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

   The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Mercy Family Clinic, Dallas, Texas

   Locations

   42 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07215559 on ClinicalTrials.gov

5. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Velocity Clinical Research, Dallas, Dallas, Texas

   Locations

   157 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07282600 on ClinicalTrials.gov

6. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

7. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

   The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   UT Southwestern Med Center, Dallas, Texas

   Locations

   74 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07533175 on ClinicalTrials.gov

8. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Thyroid Endocrinology and Diabetes, Dallas, Texas

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

9. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Cedar Health Research, LLC, Dallas, Texas

   Locations

   87 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

10. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Velocity Clinical Research, Dallas, Dallas, Texas

    Locations

    162 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07321886 on ClinicalTrials.gov

11. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mercy Family Clinic, Dallas, Texas

    Locations

    81 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07509307 on ClinicalTrials.gov

12. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    FutureSearch Trials of Dallas, Dallas, Texas

    Locations

    40 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov